Skip left side navigation and go to content

LEGISLATIVE UPDATE

August 2005


Fiscal Year (FY) 2006 Appropriations
  • Departments of Labor, Health and Human Services, and Education 2005 appropriations act (H.R. 3010)
NHLBI Programs
  • Pulmonary Hypertension Research Act of 2005 (H.R. 3005)
  • Family Asthma Act (S. 1489)
NIH Activities or Structure
  • Fair Access to Clinical Trials Act (H.R. 3196)
  • Lupus Research, Education, Awareness, Communication, and Healthcare Amendments of 2005 (H.R. 3307)
  • Foundation for the National Institutes of Health Improvement Act (S. 302)
  • Restore Scientific Integrity to Federal Research and Policymaking Act (S. 1358)
Human Embryonic Stem Cell Research or Human Cloning
  • Respect for Life Pluripotent Stem Cell Act of 2005 (H.R. 3144 and S. 1557)
  • Cures Can Be Found Act of 2005 (H.R. 3444)
  • Human Cloning Ban Act of 2005 (S. 1520)
New DHHS Program
  • Patient Navigator Outreach and Chronic Disease Prevention Act of 2005 (P.L. 109-18)
Biotechnology
  • Save America's Biotechnology Innovative Research Act of 2005 (H.R. 2943 and S. 1263)
  • Patent Reform Act of 2005 (H.R. 2795)
  • Project BioShield II Act of 2005 (S. 975)
Resolutions
  • Congenital heart defects (H.Res. 305)
  • Idiopathic pulmonary fibrosis (H.Con.Res. 178)
  • Bone marrow failure diseases (H.Con.Res. 179)

[Top of Page]

Fiscal Year (FY) 2006 Appropriations

On June 24, 2005, the House of Representatives passed its version of the Departments of Labor, Health and Human Services, and Education 2005 appropriations act (H.R. 3010). As requested in the President's budget, the bill includes $2,951,270 for the NHLBI. This is an increase of 0.3 percent over the $2,941,201 that the NHLBI received in FY 2005.

The Senate version, which the appropriations committee approved on July 14, includes $3,023,381 for the NHLBI.

Both the House (House Report 109-143) and Senate (Senate Report 109-103) reports mention NHLBI activities related to:
  • Blood vessel injury and repair.
  • Cooley's anemia.
  • Duchenne muscular dystrophy.
  • Heart failure.
  • Hemophilia.
  • Marfan syndrome.
  • Primary immunodeficiency diseases.
  • Pulmonary hypertension.
  • Scleroderma.
  • Stroke.

Both chambers encourage the NHLBI to develop education and awareness campaigns about chronic obstructive pulmonary disease (COPD) and about sleep.

The House report includes a provision encouraging the NHLBI to develop a diagnostic test for transmissible spongiform encephalopathies that would be suitable for screening the blood supply.

Other Senate language encourages the NHLBI to conduct more research on:
  • Bleeding and clotting disorders.
  • Bone marrow failure diseases.
  • Cardiovascular complications of conditions such as Down syndrome and type 1 diabetes.
  • Pulmonary fibrosis.

[Top of Page]

NHLBI Programs

Pulmonary Hypertension Research Act of 2005

Number: H.R. 3005
Sponsor: Representative Kevin Brady (R-TX)
Referred to: House Committee on Energy and Commerce (June 21)
Highlights: Would require the NHLBI to develop
  • centers of excellence dedicated to research on pulmonary hypertension and education of scientists, health professionals, and public members interested in pulmonary hypertension.
  • a clearinghouse to disseminate information about pulmonary hypertension to health professionals, patients, industry, and the public.
  • a system for collection, storage, analysis, retrieval, and dissemination of data derived from patient populations with pulmonary hypertension.

Family Asthma Act

Number: S. 1489
Sponsor: Senator Hillary Rodham Clinton (D-NY)
Referred to: Senate Committee on Health, Education, Labor, and Pensions (July 26)
Highlights: Would require the
  • National Asthma Education and Prevention Program (NAEPP) to catalog all asthma prevention, management, and surveillance activities conducted by organizations or agencies that participate in the NAEPP and to make recommendations to the Congress for strengthening and better coordinating federal asthma activities.
  • National Institute of Environmental Health Sciences (NIEHS), in collaboration with the NHLBI and other Institutes, to support additional research on gene-environment interactions that contribute to the development or exacerbation of asthma.

[Top of Page]

NIH Activities or Structure

Fair Access to Clinical Trials Act

Number: H.R. 3196
Sponsor: Representative Henry Waxman (D-CA)
Referred to: House Committee on Energy and Commerce (June 30)
Highlights: Would expand the scope of ClinicalTrials.gov and establish a database of clinical trial results. It is similar, but not identical, to S. 470, the Fair Access to Clinical Trials Act of 2005 or the FACT Act, which was introduced February 28.

Lupus Research, Education, Awareness, Communication, and Healthcare Amendments of 2005

Number: H.R. 3307
Sponsor: Representative Ileana Ros-Lehtinen (R-FL)
Referred to: House Committee on Energy and Commerce (July 14)
Highlights: Like the companion measure S. 756, which was introduced on April 11, H.R. 3307 would require the
  • NIH to expand its research portfolio to improve understanding and treatment of lupus.
  • Department of Health and Human Services (DHHS) Office of Women's Health, in collaboration with the Lupus Foundation of America, Inc., and the NIH National Center on Minority Health and Health Disparities, to develop a national campaign to raise awareness about lupus.

Foundation for the National Institutes of Health Improvement Act

Number: S. 302
Sponsor: Senator Edward Kennedy (D-MA)
Referred to: House Committee on Energy and Commerce (July 28) after passage in the Senate.
Highlights: Would require the NIH Director to transfer $500,000 yearly to the Foundation (a non-profit organization that supports a broad portfolio of public-private partnerships to complement and enhance NIH priorities and activities).

Restore Scientific Integrity to Federal Research and Policymaking Act

Number: S. 1358
Sponsor: Senator Richard Durbin (D-IL)
Referred to: Senate Committee on Homeland Security and Governmental Affairs (June 30)
Highlights: Would prohibit
  • political interference with scientific research by federal employees.
  • use of "litmus tests" for the appointment of members to federal scientific advisory committees.
Representative Henry Waxman (D-CA) introduced a similar bill, H.R. 839, on February 16.

[Top of Page]

Human Embryonic Stem Cell Research or Human Cloning

Respect for Life Pluripotent Stem Cell Act of 2005

Numbers: H.R. 3144 and S. 1557
Sponsors: Representative Roscoe Bartlett (R-MD) and Senator Tom Coburn (R-OK)
Referred to: House Committee on Energy and Commerce (June 30) and Senate HELP Committee (July 29)
Highlights: Would require the NIH to conduct and support research on ways to derive human pluripotent stem cells without harming human embryos.

Cures Can Be Found Act of 2005

Number: H.R. 3444
Sponsor: Representative Ron Paul (R-TX)
Referred to: House Committee on Ways and Means (July 26)
Highlights: Would provide tax credits to
  • individuals who donate umbilical cord blood to research organizations or cell storage facilities that do not study or store human embryonic stem cells.
  • individuals who donate money to the facilities.
  • businesses that establish or maintain the facilities.

Human Cloning Ban Act of 2005

Number: S. 1520
Sponsor: Senator Dianne Feinstein (D-CA)
Referred to: Senate Committee on the Judiciary (July 27)
Highlights: Would prohibit
  • research on human cloning.
  • interstate shipment or exportation of certain cells for human cloning.
  • exportation of unfertilized blastocysts to a country that does not prohibit human cloning.

[Top of Page]

New DHHS Program

Patient Navigator Outreach and Chronic Disease Prevention Act of 2005

Number: P.L. 109-18 (formerly H.R. 1812 and S. 898)
Date Signed: June 30, 2005
Highlights: Would require the Health Resources and Services Administration, with input from the Indian Health Service, the National Cancer Institute, and “such other offices and agencies as deemed appropriate by the Secretary,” to fund programs to reduce barriers to
  • early detection of cancer and chronic diseases, including cardiovascular diseases, for populations affected by health disparities.
  • treatment and follow-up care services for those who have cancer or other chronic diseases.

[Top of Page]

Biotechnology

Save America's Biotechnology Innovative Research Act of 2005

Numbers: H.R. 2943 and S. 1263
Sponsors: Representative Sam Graves (R-MO) and Senator Christopher Bond (R-MO)
Referred to: House Committee on Small Business and House Committee on Science and Senate Committee on Small Business and Entrepreneurship (June 16)
Highlights: Would amend the Small Business Act to allow additional businesses to be eligible to receive federal funding, including grants from the NIH, under the Small Business Innovation Research (SBIR) Program.

Patent Reform Act of 2005

Number: H.R. 2795
Sponsor: Representative Lamar Smith (R-TX)
Referred to: House Committee on the Judiciary (June 8)
Highlights: Would change the U.S. patent system for determining, in the case of multiple patent applications for a single invention, who should receive the patent by changing it from a "first-to-invent" system to a "first-inventor-to-file" system.

Project BioShield II Act of 2005

Number: S. 975
Sponsor: Senator Joseph Lieberman (D-CT
Referred to: Senate HELP Committee (April 29)
Highlights: Would provide incentives to increase private sector research to prevent, detect, contain, and treat illnesses associated with biological, chemical, nuclear, or radiological weapons attacks or an infectious disease outbreak.

[Top of Page]

Resolutions

A resolution supporting the goals and ideals of the National Congenital Heart Defect Awareness Week.

Number: H.Res. 305
Sponsor: Representative Robert Andrews (D-NJ)
Referred to: House Committee on Energy and Commerce (June 7)

Concurrent resolution recognizing the need to pursue research into the causes, a treatment, and an eventual cure for idiopathic pulmonary fibrosis, supporting the goals and ideals of National Idiopathic Pulmonary Fibrosis Awareness Week, and for other purposes.

Number: H.Con.Res. 178
Sponsor: Representative Charlie Norwood (R-GA)
Referred to: House Committee on Energy and Commerce (June 14)

Concurrent resolution expressing the sense of the Congress regarding bone marrow failure diseases.

Number: H.Con.Res. 179
Sponsor: Representative Sherrod Brown (D-OH)
Referred to: Referred to House Committee on Energy and Commerce (June 16)

Please send us your feedback, comments, and questions by using the appropriate link on the page, Contact the NHLBI.

Note to users of screen readers and other assistive technologies: please report your problems here.

Content last modified: 8/26/2005
[Top of Page]
[Legislative Update (October 2005)]
[Legislative Update (June 2005)]
NHLBI Express






Twitter iconTwitterExternal link Disclaimer         Facebook iconFacebookimage of external link icon         YouTube iconYouTubeimage of external link icon         Google+ iconGoogle+image of external link icon